NeuBase Therapeutics

NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company specializing in the development of gene silencing therapies using its innovative modular antisense technology platform. This platform is designed to tackle rare genetic diseases caused by mutant proteins through a unified approach that combines the benefits of synthetic methodologies with the precision of antisense technologies. NeuBase's focus includes addressing repeat expansion disorders, particularly Huntington's Disease and Myotonic Dystrophy, as well as dominant genetic disorders. The company's synthetic antisense oligonucleotides aim to provide targeted solutions for these challenging conditions, positioning NeuBase as a key player in the advancement of therapies for rare genetic diseases.